Dr Barbara Eichhorst at ASH 2014: Final analysis of the international phase III CLL10 study

At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Barbara Eichhorst (University Hospital, Cologne, Germany) discusses the final analysis of the international, randomised, phase III CLL10 study.

It is concluded that frontline chemoimmunotherapy with fludarabine, cyclophosphamide and rituximab (FCR) has superior efficacy (higher complete response rates, more minimal residual disease [MRD] negativity, longer progression-free survival) versus bendamustine and rituximab in previously untreated and physically fit patients with advanced chronic lymphocytic leukaemia.

Year of Production:
Running Time:
Color/Sound:

2015
1:54
Color/Sound

Comments are closed.